Segment Information - Schedule of Company Revenue and Adjusted EBITDA by Segment (Details) - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2021
Segment Revenue
Recognized revenue		$ 299,489	$ 271,893	$ 243,920
Segment Adjusted EBITDA
Total Adjusted EBITDA		(161,301)	(150,740)	(76,525)
Net loss		(311,656)	(217,490)	(183,619)
Adjustments
Interest income, net		(9,676)	(277)	(255)
Other (income) expense, net		93	83	(1,322)
Change in fair value of warrant liabilities		0	(32,989)	0
Income tax benefit		(2,772)	(3,480)	0
Depreciation and amortization		20,239	18,899	20,246
Amortization of acquired intangible assets		16,486	7,269	0
Impairment of acquired intangible assets		9,968	0	0
Stock-based compensation expense		116,017	57,933	88,425
Acquisition-related costs	[1]	0	9,362	0
Litigation settlement	[2]	0	9,950	0
Total Adjusted EBITDA		(161,301)	(150,740)	(76,525)
Consumer And Research Services
Segment Revenue
Recognized revenue		299,489	271,893	243,866
Segment Adjusted EBITDA
Total Adjusted EBITDA		(17,997)	(30,112)	12,796
Therapeutics
Segment Revenue
Recognized revenue			0	54
Segment Adjusted EBITDA
Total Adjusted EBITDA		(88,503)	(76,944)	(58,734)
Unallocated Corporate [Member]
Segment Adjusted EBITDA
Total Adjusted EBITDA	[3]	$ (54,801)	$ (43,684)	$ (30,587)

[1] For the fiscal year ended March 31, 2022, acquisition-related costs primarily consisted of advisory, legal and consulting fees.

[2] For the fiscal year ended March 31, 2022, litigation settlement is litigation cost net of insurance recoveries, which is not expected to occur on a recurring basis and not part of the Company's normal and continued business activity.

[3] Certain expenses such as Finance, Legal, Regulatory and Supplier Quality, Corporate Communications, and CEO Office are not reported as part of the reporting segments as reviewed by the CODM. These amounts are included in Unallocated Corporate.